18F-FES and 18F-FDG PET for Prediction of PFS After Fulvestrant Therapy in Patients With HR+/HER2− MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Frontiers in Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dual Tracers of 16α-[18F]Fluoro-17β-Estradiol and [18F]Fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer
Front Oncol 2020 Dec 01;[EPub Ahead of Print], C Liu, X Xu, H Yuan, Y Zhang, Y Zhang, S Song, Z YangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.